Chaiyasoot, Kusuma
Sakai, Naomi S.
Zakeri, Roxanna
Makaronidis, Janine
Crisóstomo, Luís
Alves, Marco G.
Gan, Wei
Firman, Chloe
Jassil, Friedrich C.
Hall-Craggs, Margaret A.
Taylor, Stuart A.
Batterham, Rachel L. http://orcid.org/0000-0002-5477-8585
Funding for this research was provided by:
Rosetrees Trust (CM710)
National Institute for Health and Care Research (RP-2015-06-005)
Sir Jules Thorn Charitable Trust
Article History
Received: 10 September 2023
Revised: 4 October 2023
Accepted: 11 October 2023
First Online: 1 November 2023
Declarations
:
: RLB reports receiving consulting fees from Pfizer, Eli-Lilly, Gila Therapeutics Inc., and ViiV Healthcare and consulting fees, lecture fees from Novo Nordisk and participating in clinical trials for Novo Nordisk, from May 2023 she is a full-time employee and shareholder for Eli Lilly and Company Ltd, Basingstoke UK. SAT reports shareholding in Motilent and consultant fees from AstraZeneca, unrelated to the current work. As of February 2023, WG is a full-time employee of Novo Nordisk. All other authors report no conflicts of interest.